Modifications of Apoprotein, Lipoprotein Parameters and HDL2 and HDL3 Subfractions During Treatment with Bezafibrate Retard
Bezafibrate is today one of the most commonly used hypolipidemic drugs in the treatment of type IIA, IIB and IV hyperlipidemias. This depends on the specific activity of this drug. Bezafibrate in fact has a selective hypolipidemic activity according to the hyperlipemic phenotype: in type IIA it mainly reduces TC (total cholesterol) levels, while in types IIB and IV it decreases especially TG (triglycerides) levels. Bezafibrate is also able to increase HDL-C (Fellin et al. 1981; Mannarino et al. 1982) and to modify apoprotein patterns: apo A1 generally increases (Weisweiler et al. 1980) in hypertriglyceridemic patients. Recently, a slow preparation of Bezafibrate has been prepared to allow the administration of a single daily dose (400 mg) (Ledermann and Kaufmann 1981). The aim of our study was to investigate the effects of Bezafibrate Retard (BfR) administration on both lipoproteins and apoproteins in three groups of patients affected by primary hyperlipidemias.
KeywordsSingle Daily Dose Plasma High Density Lipoprotein Isocaloric Diet Hypolipidemic Drug Single Radial Immunodiffusion
- Abell LL, Levy BB, Kendal FE (1952) A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem 195:357–363Google Scholar
- Fellin R, Martini S, Crepaldi G, Senin U, Mannarino E, Avellone G, Notarbartolo A, Capurso A, D’Agostino C, Montaguti U, Celin D, Descovich GC, Mantovani E (1981) Multicenter trial with Bezafibrate in primary hyperlipidemias. Curr Ther Res 29:657–665Google Scholar
- Mannarino E, Senin U, Fioroni G, Ventura S (1982) Effects of Bezafibrate treatment on lipids and lipoproteins. In: Crepaldi G, Greten H, Schettler G, Baggio G (eds) Lipoproteins metabolism and therapy of lipids discorders. Int Symp 16–17 April 1982, Florence. Excerpta Medica, Amsterdam Oxford Princeton, pp 113–119Google Scholar
- Wahlefeld AW (1974) Determination after enzymatic hydrolysis. In: Bergmeyer HU (ed) Methods of enzymatic analysis, 2nd Engl edn. Chemie, Weinheim; and Academic Press, London, New York, p 1831Google Scholar
- Weisweiler P, Schwandt P (1980) Lipoprotein lipids and apolipoproteins after six months treatment with Bezafibrate. Artery 6:402–408Google Scholar